Why AML Still Needs New Targets After FLT3 and IDH

Acute myeloid leukemia (AML) arises from clonal expansion of myeloid progenitors that fail to differentiate normally, driven by multiple distinct genomic events. FLT3 mutations — including internal tandem duplications (ITD) and tyrosine kinase domain (TKD) point mutations — are found in approximately 25–30% of AML patients, making them the most frequently cited genetic events in the current patent and literature dataset. IDH1 and IDH2 mutations represent another molecularly defined subset. Yet even combining these two target populations leaves the majority of AML patients without an actionable mutation addressed by approved targeted therapy.

The scale of the unmet need is illustrated by the RATIFY trial data referenced in a 2025 patent by Weisberg E. (EP): midostaurin combined with daunorubicin/cytarabine produced a median overall survival of 74.7 months in FLT3-mutated newly diagnosed AML, versus 26.0 months in the placebo arm. This result, while meaningful for the FLT3-mutated subset, simultaneously underscores how critical it is to develop effective strategies for the broader AML population that cannot benefit from FLT3 inhibition.

Downstream signaling cascades activated by FLT3-ITD — including STAT5, RAS/MAPK, and PI3K/AKT pathways — are highlighted across retrieved results as mediators of blast survival and differentiation arrest. The Oregon Health & Science University patent (2023) further establishes that drug sensitivity in AML is broadly governed by cell differentiation state, which directly explains why agents that restore differentiation — such as menin inhibitors and DOT1L inhibitors — may complement cytotoxic or pro-apoptotic approaches rather than simply replacing them.

Menin–MLL Inhibition: The Strongest Signal Beyond FLT3 and IDH

Menin inhibitors are the most explicitly described “beyond FLT3 and IDH” target class in the retrieved dataset, supported by academic literature from the University of Cambridge (2021) that identifies the menin–MLL axis as a validated therapeutic target across multiple AML genotypes. Menin (encoded by MEN1) acts as a chromatin adaptor: MLL-fusion proteins tether to HOXA and MEIS1 target loci through direct interaction with menin’s N-terminal binding domain. Small-molecule inhibitors block this protein–protein interaction, suppressing HOXA cluster and MEIS1 gene expression and triggering differentiation and anti-proliferative effects.

The Cambridge paper identifies a broad patient population rationale for menin inhibition: NPM1c-mutated AML, NUP98-NSD1 AML, MLL-PTD AML, IDH1/2-mutated AML, and DNMT3A-mutated AML all exhibit HOX-cluster dependence amenable to this approach. NPM1c-mutated and NUP98-NSD1 AML together represent a substantial fraction of AML cases without FLT3 or IDH mutations — precisely the population that current approved targeted therapies cannot adequately address.

“Menin inhibition represents the most mechanistically validated ‘beyond FLT3/IDH’ target in this dataset, with a broad patient population rationale spanning NPM1c, NUP98-NSD1, MLL-rearranged, and DNMT3A-mutated AML.”

The Cambridge paper also describes mechanistic synergy between menin inhibitors and DOT1L inhibitors: menin inhibitors block MLL-fusion tethering while DOT1L inhibition removes the H3K79me2 mark at MLL target genes. These approaches target the same transcriptional programme via complementary mechanisms, and signals in the retrieved literature suggest interest in combination exploration. According to WIPO filing data, IP coverage specifically in the menin inhibitor space is underrepresented in the retrieved results — suggesting potential freedom-to-operate in peripheral claim spaces, formulation strategies, or combination patents.

BCL-2 and MCL-1: From Novel Target to Backbone Combinant

BCL-2 inhibition with venetoclax has shifted from a novel targeted approach to a backbone combinant in AML therapy — a transition documented clearly across multiple 2022–2024 patents in this dataset. The F. Hoffmann-La Roche anti-CD25 antibody patent (2024) explicitly names venetoclax, FLT3 inhibitors, IDH inhibitors, and hypomethylating agents as the current standard-of-care landscape against which new agents must compete, confirming that BCL-2 inhibition is now a reference point rather than a frontier target.

The RIKEN patent (Japan, 2022) provides mechanistic depth on why BCL-2 inhibition alone is insufficient in FLT3-mutated AML: HCK kinase (hematopoietic cell kinase) is identified as a compensatory survival node that is activated when BCL-2 is blocked, driving adaptive resistance. The RIKEN filing describes in vitro and in vivo preclinical activity of HCK inhibitors combined with BCL-2 inhibitors in FLT3-mutated AML — representing IND-enabling evidence for a combination strategy targeting this compensatory pathway.

MCL-1-specific inhibitors, another BH3-mimetic class with significant published interest according to Nature and other scientific literature, are not directly named in the retrieved results. This represents either an IP gap or a search-coverage limitation that warrants dedicated investigation. The distinction matters commercially: MCL-1 is the primary resistance mechanism to venetoclax in AML, and compounds that selectively target MCL-1 would address a well-characterised unmet need in the post-venetoclax resistance setting.

DOT1L, IRAK/FLT3, and MDM2: Emerging Resistance-Driven Strategies

Three additional target classes in the retrieved dataset address specific resistance mechanisms or molecular vulnerabilities in AML subsets: DOT1L inhibitors targeting H3K79 methylation, dual IRAK/FLT3 inhibitors addressing adaptive resistance in U2AF1-mutated disease, and MDM2 inhibitors exploiting p53 pathway retention in FLT3-ITD cells.

DOT1L Inhibition

DOT1L is an H3K79 methyltransferase essential for MLL-rearranged AML gene expression programmes. The Cambridge chromatin regulation paper describes how DOT1L inhibition reduces H3K79me2 at MLL target genes, correlating with anti-proliferative effects in MLL-r AML. A Memorial Sloan Kettering Cancer Center patent (2020, JP) extends this rationale beyond MLL-rearranged disease: leukemias without MLL translocations but with elevated HOX cluster gene expression are proposed as a targetable population, significantly broadening the patient stratification strategy. A King’s College London patent (2017, WO) formalises a companion biomarker approach by claiming the combination of a PARP inhibitor with a DOT1L inhibitor specifically for AML with chromosomal abnormalities at 11q23 (the MLL locus).

Dual IRAK/FLT3 Inhibition

Kurome Therapeutics (US) is the most prolific recent filer in this dataset, with multiple IL and CN patents filed between 2023 and 2026 covering dual IRAK1/4 and FLT3 inhibitors. The mechanistic rationale is specific: IRAK4-Long isoform expression, driven by U2AF1 mutations, constitutes an adaptive resistance escape route for FLT3 inhibitor monotherapy. Dual inhibitors co-targeting IRAK and FLT3 are designed to block this compensatory signalling simultaneously. The Kurome filings also reference CDK9 pathway dysregulation as an additional AML vulnerability, with alvocidib cited as a CDK9 inhibitor combination partner — signalling emerging interest in transcriptional kinase co-targeting as a third axis of combination therapy.

MDM2 Inhibitors and p53 Reactivation

A University of Michigan patent (2013, JP) identifies FLT3-ITD mutation as a predictive biomarker for sensitivity to MDM2 inhibitors, proposing that p53 pathway activation in FLT3-ITD cells — which retain wild-type p53 — provides synthetic lethality. A Daiichi Sankyo patent (2023, CN) formalises this as a clinical combination strategy, claiming a spirooxindole-derived MDM2 inhibitor combined with a FLT3 inhibitor. Both sources converge on FLT3-ITD as a positive predictive biomarker for MDM2 inhibitor sensitivity, establishing a genetically defined rationale for co-targeting. Standards bodies including ISO and regulatory frameworks from the FDA increasingly require such companion biomarker strategies to be pre-specified in combination therapy development programmes.

Combination Scheduling and the IP Implications of Sequencing

Combination regimens — particularly triple combinations anchored on a hypomethylating agent (HMA) backbone — have become the reference framework against which new AML agents are benchmarked. The FLT3-HDAC dual inhibitor patent from Shandong University (2025, CN) explicitly references azacitidine/venetoclax/gilteritinib and azacitidine/venetoclax/quizartinib triple combinations (NCT05520567, NCT03661307) as established clinical comparators, confirming that triple-drug combinations are now the competitive standard in FLT3-mutated AML.

A strategically significant development in the Celgene/Bristol Myers Squibb azacitidine combination patent (2022, CN) is the formalisation of dosing schedule as a distinct IP element. The patent describes synergistic activity data for azacitidine plus FLT3 inhibitors (midostaurin, gilteritinib) in MV4-11 and MOLM-13 AML cell models, with sequential dosing — azacitidine on days 1–3 followed by the FLT3 inhibitor on day 4 — producing the maximal synergistic effect. This trend has direct implications for generic and biosimilar strategy: dosing schedule and sequencing are becoming IP-protectable elements independent of compound composition claims.

“Sequential dosing — azacitidine on days 1–3 followed by a FLT3 inhibitor on day 4 — is being formalised in patent claims, signalling that combination scheduling itself is becoming a protectable IP element distinct from compound composition.”

Additional emerging combination directions identified in the dataset include: menin inhibition plus DOT1L inhibition (mechanistic synergy from complementary chromatin regulatory mechanisms); IRAK/FLT3 dual inhibition plus CDK9 inhibitors (alvocidib cited as a partner); MDM2 plus FLT3 inhibitor combinations in FLT3-ITD disease; and antibody-based approaches — including FLT3-targeted CAR-T cells combined with secreted anti-PD-1/PD-L1 antibodies — layered onto small-molecule backbones. The NIH National Cancer Institute maintains active clinical trial registrations for several of these combination strategies, providing a public benchmark for development stage assessment.

Protein Degraders and the PROTAC Gap in the AML Patent Landscape

Protein degrader approaches — including PROTACs (proteolysis-targeting chimeras) and related molecular glue platforms — are conspicuously absent from the retrieved patent and literature dataset. This absence is notable because PROTAC strategies targeting AML-relevant proteins such as FLT3, BRD4, and BCL-2 family members represent a major area of published academic and commercial interest, documented in peer-reviewed literature indexed by PubMed/NCBI.

The strategic implication is significant: the PROTAC gap in this dataset should not be interpreted as an absence of IP activity in the broader field. Targeted protein degraders have attracted substantial investment from both academic groups and commercial organisations, and the absence of these results in the current dataset most likely reflects a search-coverage limitation. Organisations conducting freedom-to-operate or landscape analyses in the AML space should commission dedicated degrader-focused searches to characterise this segment — particularly given that PROTAC approaches to FLT3 degradation could directly compete with or complement the kinase inhibitor strategies that dominate the current retrieved dataset.

The PEAR1 biomarker identified in the Oregon Health & Science University patent (2023) — PEAR1 RNA expression as a predictor of clinical outcome in AML patients under 45 years — illustrates a parallel trend: differentiation-state biomarkers with potential drug stratification utility are emerging alongside novel therapeutic modalities. As protein degrader and other novel-modality programmes advance, companion biomarker strategies of this type will become increasingly important for patient selection and regulatory approval, consistent with frameworks established by the EMA and FDA for precision oncology approvals.